Advertisement
Advertisement
U.S. Markets close in 3 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Allarity Therapeutics, Inc. (ALLR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.2475-0.0025 (-1.00%)
As of 12:15PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2500
Open0.2458
Bid0.2475 x 1000
Ask0.2498 x 800
Day's Range0.2370 - 0.2528
52 Week Range0.2000 - 9.6700
Volume521,170
Avg. Volume2,105,711
Market Cap1.999M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

    Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today announced that the Company’s 2023 Annual Meeting of Stockholders (the “Meeting”), on January 19, 2023, at 1:00 p.m. (Eastern Time) was adjourned without any business being conducted. The Meeting was adjourned until Frid

  • GlobeNewswire

    Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

    PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the Company’s adjourned 2022 Annual Stockholders Meeting (“2022 ASM”) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (“2023 ASM”) will be held, as

  • GlobeNewswire

    Allarity Therapeutics Reports Third Quarter 2022 Financial Results

    Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity’s cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expense

Advertisement
Advertisement